Special Issue

Small Molecules as Antimicrobials 2024

Message from the Guest Editor

This Special Issue, "Small Molecules as Antimicrobials", delves into the latest advancements and research breakthroughs in the development and application of small molecules to combat microbial infections. By focusing on small molecules, this Special Issue aims to highlight the versatility and potential of these compounds in addressing some of the most pressing challenges in infectious disease management. The insights gained from the featured studies are expected to pave the way for the development of next-generation antimicrobials that are more effective, less prone to resistance, and safer for clinical use.

Potential topics include, but are not limited to, the following:

Reports on novel small molecules with potent antimicrobial activity discovered through various approache.

Discussions on the optimization of lead compounds to enhance efficacy, reduce toxicity, and improve pharmacokinetic properties.

Research on advanced delivery systems for small molecule antimicrobials, including nanoparticles, liposomes, and targeted delivery methods to enhance bioavailability and reduce side effects.

Guest Editor

Dr. Poce Giovanna

Department of Chemistry and Technology of Drugs (DCTF), Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions

closed (15 December 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/208232

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

